| answer text |
<p>The Medicines and Healthcare products Regulatory Agency (MHRA) have received 124
spontaneous reports of suspected adverse drug reactions (ADRs) via the Yellow Card
Scheme from prescribers and patients in association with liothyronine in the United
Kingdom as of 28 January 2018. The MHRA have not received any spontaneous cases where
the reporter has stated their liothyronine is unlicensed.</p><p> </p><p>Of the 124
reports, six relate to a brand of liothyronine that is not licensed in the UK. However,
it is important to note that patients may have been prescribed a medication while
in a foreign country; therefore, a report of a foreign brand cannot be assumed as
unlicensed use. Furthermore, while reporters are requested to provide as much detail
as possible, detail of the medicinal brand or license is not a compulsory reporting
criteria. Therefore, this information is not always provided.</p><p> </p><p>Yellow
Card data should not be used as an indicator of the frequency of suspected ADRs to
medicines. The level of ADR reporting may fluctuate over time due to a variety of
reasons such as a medicine being new, stimulated interest/publicity and variations
in exposure to the medicine.</p>
|
|
